{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:15:30Z","timestamp":1761178530016,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.canrad.2016.07.090","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T22:31:36Z","timestamp":1473373896000},"page":"530-534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radioth\u00e9rapie des lymphomes malins non hodgkiniens ganglionnaires folliculaires et diffus de stade limit\u00e9"],"prefix":"10.1016","volume":"20","author":[{"given":"C.","family":"Demoor-Goldschmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Agape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Barillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2016.07.090_bib0005","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2015.64.9418","article-title":"Re-examining the role of radiation therapy for diffuse large B-Cell lymphoma in the modern era","volume":"34","author":"Ng","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0010","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.3109\/10428194.2013.779687","article-title":"Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma","volume":"54","author":"Shi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.canrad.2016.07.090_bib0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdq389","article-title":"The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67\u00a0scans","volume":"22","author":"Dorth","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0020","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","article-title":"Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy","volume":"28","author":"Phan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0025","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.29113","article-title":"Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project","volume":"121","author":"Dabaja","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2016.07.090_bib0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2014.12.042","article-title":"Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma","volume":"92","author":"Kwon","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2016.07.090_bib0035","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1200\/JCO.2015.61.7654","article-title":"Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma: do we still need consolidative radiotherapy?","volume":"33","author":"Vargo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0040","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3109\/10428194.2015.1120866","article-title":"The role of radiotherapy for patients over age 60\u00a0with diffuse large B-cell lymphoma in the rituximab era","volume":"57","author":"Cassidy","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.canrad.2016.07.090_bib0045","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clml.2015.12.008","article-title":"Doxorubicin-based chemotherapy and radiation therapy produces favorable outcomes in limited-stage plasmablastic lymphoma: a single-institution review","volume":"16","author":"Pinnix","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.canrad.2016.07.090_bib0050","series-title":"ASH Annual Meeting","article-title":"R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B cell lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02-03\u00a0trial from the Lysa\/Goelams Group","author":"Lamy","year":"2014"},{"key":"10.1016\/j.canrad.2016.07.090_bib0055","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/10428194.2014.930853","article-title":"Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients","volume":"56","author":"Odejide","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.canrad.2016.07.090_bib0060","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","author":"Held","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2016.07.090_bib0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO Guidelines consensus conference on malignant lymphoma 2011\u00a0part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)","volume":"24","author":"Ghielmini","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0080","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0085","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3\u00a0trial","volume":"378","author":"Recher","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2016.07.090_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2016.1153088","article-title":"Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs R-chemotherapy plus radiotherapy","volume":"57","author":"Ciammella","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.canrad.2016.07.090_bib0095","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood.V124.21.392.392","article-title":"Phase 2\u00a0trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC)","volume":"124","author":"Sehn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2016.07.090_bib0100","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/leu.2015.120","article-title":"PET\/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: an analysis of 106\u00a0patients regarding prognostic significance and implications for subsequent radiotherapy","volume":"30","author":"Vassilakopoulos","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.canrad.2016.07.090_bib0105","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1200\/JCO.2005.05.3470","article-title":"Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma","volume":"24","author":"Leahy","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.leukres.2015.05.009","article-title":"The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment","volume":"39","author":"Sancho","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.canrad.2016.07.090_bib0115","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3109\/10428194.2014.990010","article-title":"Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?","volume":"56","author":"Janikova","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.canrad.2016.07.090_bib0120","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1002\/cncr.29491","article-title":"What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?","volume":"121","author":"Vargo","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2016.07.090_bib0125","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage. Grades 1\u20132\u00a0follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2016.07.090_bib0130","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.25149","article-title":"Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis","volume":"116","author":"Pugh","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2016.07.090_bib0135","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1023\/A:1008341725612","article-title":"Individuality versus conformity. Is perfection necessary in staging and prognostic classifications of specific primary extranodal lymphomas?","volume":"10","author":"Gospodarowicz","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0140","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for Stages I\u2013II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2016.07.090_bib0145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14712598.2013.786698","article-title":"Rituximab in the treatment of non-Hodgkin's lymphoma\u00a0\u2013\u00a0a critical evaluation of randomized controlled trials","volume":"13","author":"Griffin","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.canrad.2016.07.090_bib0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-2407-11-87","article-title":"Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial","volume":"11","author":"Witzens-Harig","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2016.07.090_bib0155","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0160","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4Gy versus 24Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3\u00a0non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijrobp.2012.12.024","article-title":"Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure","volume":"86","author":"Russo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2016.07.090_bib0170","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy","volume":"116","author":"Campbell","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2016.07.090_bib0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0360-3016(00)01383-3","article-title":"Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy","volume":"49","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2016.07.090_bib0180","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0167-8140(95)01600-L","article-title":"Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma","volume":"36","author":"Pendlebury","year":"1995","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0185","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijrobp.2015.07.2265","article-title":"Management trends and outcomes for stages I to II mantle cell lymphoma using the National Cancer Data Base: ascertaining the ideal treatment paradigm","volume":"93","author":"Gill","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2016.07.090_bib0190","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stages I\u2013II indolent non-Hodgkin's lymphoma","volume":"21","author":"Seymour","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2016.07.090_bib0195","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3109\/10428194.2012.743657","article-title":"Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma","volume":"54","author":"Xu","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.canrad.2016.07.090_bib0200","doi-asserted-by":"crossref","first-page":"20150409","DOI":"10.1259\/bjr.20150409","article-title":"Evolution of radiation techniques in the treatment of mediastinal lymphoma: from 3D conformal radiotherapy (3DCRT) to intensity-modulated RT (IMRT) using helical tomotherapy (HT): a single-centre experience and review of the literature","volume":"89","author":"Besson","year":"2016","journal-title":"Br J Radiol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321816303687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321816303687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:28:25Z","timestamp":1761136105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321816303687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":40,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1278321816303687"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2016.07.090","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioth\u00e9rapie des lymphomes malins non hodgkiniens ganglionnaires folliculaires et diffus de stade limit\u00e9","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2016.07.090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}